

10/10/11
U.S. PTO

12-06-09

A

UTILITY PATENT
APPLICATION TRANSMITTAL
(Under 37 C.F.R. §1.53(b))

Docket No.: ECV-5630 Page 1 of 2
Title: Methods for Preparation of Bioprosthetic Tissue and
Implantable Devices Comprising such Bioprosthetic Tissue
Express Mail Label No.: EL599141800US

APPLICATION ELEMENTS

INVENTORS: Crystal M. Cunanan, Tan Thanh Dinh, Christine Loshbaugh, H. Chris Sarner, Michael N. Helmus, Christine M. Cabling

<input checked="" type="checkbox"/>	Fee Transmittal Form (Submit an original, and a duplicate for fee processing)	11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations
2. <input checked="" type="checkbox"/>	Specification [Total Pages 45]	12. <input type="checkbox"/> Preliminary Amendment
3. <input type="checkbox"/>	Drawing(s) (35 USC §113) [Total Pages (Figs. 1-____)]	13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503)
4. <input type="checkbox"/>	Signed Declaration [Total Pages <input type="checkbox"/>]	14. <input type="checkbox"/> Small Entity Statement(s)
a. <input type="checkbox"/>	Newly executed (original or copy)	15. <input type="checkbox"/> Certified Copy of Priority Documents (s)
b. <input type="checkbox"/>	Copy from a prior application (37 CFR §1.63(d))	16a. <input type="checkbox"/> Cancel in the application original claims _____ before calculating the filing fee
i. <input type="checkbox"/>	<u>(Note Box 5 below)</u> <u>DELETION OF INVENTOR(S)</u>	16b. <input type="checkbox"/> Amend the specification by inserting before the first line the sentence: --This is a ___ Continuation, ___ Divisional, ___ Continuation-in-part, of application _____, filed _____
Signed statement attached deleting inventor named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)		
5. <input type="checkbox"/>	Incorporation By Reference (useable if Box 4b is checked.) entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein	16c. <input type="checkbox"/> I hereby verify that the attached papers are a true copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was Signed. I hereby verify that the papers are a true copy of the latest signed prior application number _____, filed _____ and further that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.
6. <input type="checkbox"/>	Microfiche Computer Program	16d. <input type="checkbox"/> Other: _____
7. <input type="checkbox"/>	Nucleotide and/or Amino Acid Sequence Submission	16e. <input type="checkbox"/> Other _____
8. <input type="checkbox"/>	Assignment Papers with recordation sheet (____ pages)	
9. <input type="checkbox"/>	37 CFR §3.73(b) Statement <input type="checkbox"/> Power of Attorney	
10. <input type="checkbox"/>	English Translation Document	
17. <input checked="" type="checkbox"/>	PRIORITY CLAIM: The present application claims priority under 35 USC § 119 to U.S. Provisional Application No. 60/244,889 filed November 1, 2000, AND is a continuation-in-part of U.S. Patent Application No. 09/930,619 filed on August 15, 2001.	

UTILITY PATENT
APPLICATION TRANSMITTAL
(Under 37 C.F.R. §1.53(b))

Docket No.: ECV-5630
Page 2 of 2
Title: Methods for Preparation of Bioprosthetic Tissue and
Implantable Devices Comprising such Bioprosthetic Tissue
Express Mail Label No.: EL599141800US


CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	60 - 20=	40	X \$18 =	\$720
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	6 - 3=	3	\$84 =	\$252
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ 280 =	\$ 0
				BASIC FEE (37 CFR §1.16(a))	\$740
				TOTAL =	\$1,712

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 501225 (Docket ECV-5630)

(For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. Fees required under 37 CFR §1.16
- b. Fees required under 37 CFR §1.17
- c. Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME	John Christopher James, Reg. No. 40,660
SIGNATURE	
DATE	Oct. 30, 2001

CORRESPONDENCE ADDRESS
Edwards Lifesciences LLC
Law Dept.
One Edwards Way
Irvine, California 92614
Telephone: (949) 250-6878 Fax: (949) 250-6850

CERTIFICATE OF MAILING UNDER 37C.F.R. §1.10

I hereby certify that the above-identified document is being deposited with the United States Postal Service as Express Mail No. EL599141800US in an envelope addressed to Box Patent Application, Commissioner for Patents, Washington, D.C. 20231 on

11/01/01

By: 
Jan Lamonica